EPIVX Performance — EuroPac International Value Fund, Class A
Data updated: 2026-09-28
EPIVX returned −0.02% year to date and +20.96% over one year to Jul 2026. Annualised returns are +15.54% over 3 years and +11.17% over 5 years. The fund trailed its International Mid-Cap Value category average: $100 invested three years ago grew to $154, against $157 for the category, and to $121 over one year, against $123. Volatility over the past three years was 15.01% a year. In the 12 months to Jul 2026 the fund took in a net $24.0M, and assets reached $197.24M.
EPIVX Growth of $100
What $100 invested in EuroPac International Value Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the International Mid-Cap Value category average over the same months.
| Period | EPIVX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $121 | $123 |
| 3 years (Aug 2023 – Jul 2026) | $154 | $157 |
| 5 years (Aug 2021 – Jul 2026) | $170 | $154 |
| Since data start (Feb 2020 – Jul 2026) | $220 | $190 |
EPIVX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −0.02% |
| 1 year | +20.96% |
| 3 years (annualised) | +15.54% |
| 5 years (annualised) | +11.17% |
EPIVX Annual Returns
Calendar-year total returns of EuroPac International Value Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | −0.02% |
| 2025 | +47.15% |
| 2024 | +5.08% |
| 2023 | +9.80% |
| 2022 | +0.47% |
| 2021 | +7.11% |
| 2020 (Feb–Dec) | +20.26% |
EPIVX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +5.1% | +6.1% | −8.4% | −0.3% | +1.1% | −7.2% | +4.6% | — | — | — | — | — |
| 2025 | +6.3% | +2.3% | +3.8% | +3.2% | +1.2% | +3.1% | +0.1% | +7.3% | +5.2% | −4.1% | +8.7% | +2.9% |
| 2024 | −4.1% | −0.4% | +5.2% | +0.1% | +3.6% | −1.9% | +6.6% | +5.3% | +1.2% | −3.8% | −1.0% | −5.0% |
| 2023 | +5.8% | −4.5% | +5.4% | +2.5% | −5.3% | +3.8% | +2.5% | −3.0% | −4.0% | −1.9% | +5.9% | +3.1% |
| 2022 | +1.9% | +2.4% | +3.8% | −3.1% | +1.4% | −8.7% | −0.1% | −3.3% | −5.8% | +3.9% | +9.4% | 0.0% |
| 2021 | −1.3% | −0.8% | +4.9% | +3.4% | +6.4% | −4.2% | −0.5% | −0.8% | −3.2% | +2.2% | −4.1% | +5.8% |
| 2020 | — | −6.3% | −11.7% | +19.5% | +3.5% | +7.0% | +5.4% | +0.2% | −3.2% | −4.6% | +7.7% | +4.4% |
EPIVX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 15.01%
- 3-year Sharpe ratio: 0.74 (vs 4.5% risk-free rate)
- Best month: +8.72% (Nov 2025)
- Worst month: −8.42% (Mar 2026)
EPIVX Fund Flows
Monthly money in and out of EuroPac International Value Fund, from SEC Form N-PORT.
- 12-month net flow: $24.0M
- 12-month gross sales (incl. reinvestments): $49.2M
- Sales ÷ redemptions: 1.95×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $916K | $1.8M | −$859K |
| Jun 2026 | $1.3M | $2.1M | −$834K |
| May 2026 | $852K | $1.7M | −$860K |
| Apr 2026 | $1.6M | $2.0M | −$446K |
| Mar 2026 | $9.3M | $3.4M | $5.9M |
| Feb 2026 | $5.8M | $2.5M | $3.3M |
| Jan 2026 | $8.6M | $1.8M | $6.8M |
| Dec 2025 | $11.3M | $1.7M | $9.6M |
| Nov 2025 | $1.1M | $1.5M | −$401K |
| Oct 2025 | $2.8M | $2.3M | $470K |
| Sep 2025 | $4.0M | $2.7M | $1.3M |
| Aug 2025 | $1.7M | $1.7M | $16K |
EPIVX Assets Under Management
Net assets of EuroPac International Value Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $197.24M |
| 2026-04-30 | $203.69M |
| 2026-01-31 | $203.14M |
| 2025-10-31 | $168.99M |
| 2025-07-31 | $154.93M |
| 2025-04-30 | $148.40M |
| 2025-01-31 | $135.78M |
| 2024-10-31 | $143.29M |
| 2024-07-31 | $142.74M |
| 2024-04-30 | $135.23M |
| 2024-01-31 | $133.84M |
| 2023-10-31 | $131.99M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.